Bristol Medical School, Public Health Science, University of Bristol, Bristol, UK.
Bristol Medical School, Translational Health Science, University of Bristol, Bristol, UK.
Int J Cardiol. 2022 Jul 15;359:20-27. doi: 10.1016/j.ijcard.2022.04.030. Epub 2022 Apr 13.
Hybrid coronary revascularization (HCR) combines the benefits of a left internal mammary artery to left anterior descending artery anastomosis, via a mini thoracotomy, with percutaneous coronary intervention (PCI) for other diseased coronaries.
The aim of this meta-analysis is to compare the short- and long-term outcomes of HCR with those of coronary artery bypass grafting (CABG) for multi-vessel coronary artery disease (MCAD).
We performed a meta-analysis with a primary outcome of short-term mortality and secondary outcomes of mid-term survival, length of hospital stay, stroke, renal failure and mid-term MACE rate.
3399 patients (HCR = 1164, CABG = 2235) were included, with no significant difference in short-term mortality between groups (OR = 1.50, 95% CI = [0.90,2.49], p = 0.11), although a higher mortality rate was seen in the HCR group (0.73% vs 0.64%). The average length of stay in intensive care unit was significantly shorter following HCR than CABG (mean difference = -15.52 h, CI = [-22.47,-8.59], p˂0.001) and overall hospital stay was also shorter in this group, although not statistically significant (mean difference = -3.15 days, 95% CI = [-6.55, 0.25], p = 0.07). HCR was associated with a reduced odds of blood transfusion (OR = 0.34, 95% CI = [0.22,0.54], p < 0.001). There was not a significant difference in mid-term survival (OR = 0.86, 95% CI = [0.62,1.21], p = 0.39) or MACE rate (OR = 0.82, 95% CI = [0.55,1.23], p = 0.34). No differences were found between HCR and CABG for post-operative stroke (OR = 1.36, 95% CI = [0.87, 2.13], p = 0.16) or renal failure (OR = 0.71, 95% CI = [0.43,1.16], p = 0.14).
HCR has a higher incidence of short-term mortality compared to CABG in patients with MCAD, although this difference is not statistically significant. Similar rates of mid-term survival and other short term post-operative complications were found between the two groups. HCR has a shorter ICU stays and reduced requirement for blood transfusion.
杂交冠状动脉血运重建(HCR)结合了经小切口左内乳动脉至前降支吻合术的优势,以及经皮冠状动脉介入治疗(PCI)治疗其他病变冠状动脉。
本荟萃分析旨在比较 HCR 与冠状动脉旁路移植术(CABG)治疗多支血管冠状动脉疾病(MCAD)的短期和长期结局。
我们进行了荟萃分析,主要结局为短期死亡率,次要结局为中期生存率、住院时间、卒中、肾功能衰竭和中期主要心脏不良事件(MACE)发生率。
共纳入 3399 例患者(HCR=1164 例,CABG=2235 例),两组短期死亡率无显著差异(OR=1.50,95%CI=[0.90,2.49],p=0.11),但 HCR 组死亡率略高(0.73% vs 0.64%)。与 CABG 相比,HCR 组患者重症监护病房(ICU)的平均住院时间明显缩短(平均差异=-15.52 h,CI=-22.47,-8.59,p˂0.001),整体住院时间也缩短,但无统计学意义(平均差异=-3.15 天,95%CI=-6.55,0.25,p=0.07)。HCR 与输血几率降低相关(OR=0.34,95%CI=[0.22,0.54],p˂0.001)。中期生存率(OR=0.86,95%CI=[0.62,1.21],p=0.39)或 MACE 发生率(OR=0.82,95%CI=[0.55,1.23],p=0.34)无显著差异。HCR 与 CABG 术后卒中(OR=1.36,95%CI=[0.87,2.13],p=0.16)或肾功能衰竭(OR=0.71,95%CI=[0.43,1.16],p=0.14)发生率无差异。
与 CABG 相比,HCR 治疗 MCAD 患者的短期死亡率更高,但差异无统计学意义。两组中期生存率和其他短期术后并发症发生率相似。HCR 患者 ICU 住院时间更短,输血需求减少。